Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Recommendation of “Buy” by Analysts

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have been given a consensus rating of “Buy” by the five analysts that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $19.80.

A number of equities analysts recently commented on the company. Maxim Group reiterated a “buy” rating and set a $12.00 price target on shares of Capricor Therapeutics in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a report on Tuesday.

Institutional Trading of Capricor Therapeutics

A number of institutional investors have recently made changes to their positions in CAPR. Vanguard Group Inc. lifted its holdings in shares of Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after acquiring an additional 200,499 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Marshall Wace LLP purchased a new stake in Capricor Therapeutics during the second quarter valued at approximately $426,000. Bank of New York Mellon Corp raised its holdings in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares during the last quarter. Finally, Jump Financial LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter worth $258,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Up 17.2 %

Capricor Therapeutics stock traded up $0.76 on Tuesday, reaching $5.17. 1,332,870 shares of the stock were exchanged, compared to its average volume of 343,455. The stock has a market cap of $165.33 million, a PE ratio of -5.86 and a beta of 3.92. The firm has a fifty day moving average price of $4.33 and a two-hundred day moving average price of $5.17. Capricor Therapeutics has a twelve month low of $2.68 and a twelve month high of $7.28.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Equities analysts anticipate that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.